Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25275134 | 0.91 | L3MBTL1 (0.44) | L3MBTL1CTSBPPARAHDAC3HDAC1 | |
| SCHEMBL25276707 | 0.88 | CCR6 (0.37) | L3MBTL1CCR6PAX8HDAC3HDAC1 | |
| SCHEMBL25250198 | 0.88 | CCR6 (0.39) | L3MBTL1CCR6PAX8ALDH1A1LMNA | |
| SCHEMBL25246646 | 0.87 | L3MBTL1 (0.35) | L3MBTL1CCR6PAX8HDAC3HDAC1 | |
| SCHEMBL25223781 | 0.87 | CCR6 (0.36) | L3MBTL1CCR6PAX8HDAC3HDAC1 | |
| SCHEMBL25221576 | 0.83 | L3MBTL1 (0.48) | L3MBTL1CTSBPPARACCR6PAX8 | |
| SCHEMBL30473565 | 0.83 | L3MBTL1 (0.43) | L3MBTL1CTSBPPARAALDH1A1LMNA | |
| SCHEMBL25225313 | 0.82 | CCR6 (0.40) | L3MBTL1CCR6PAX8HDAC3HDAC1 | |
| SCHEMBL25787817 | 0.81 | CYP3A4 (0.33) | — | |
| SCHEMBL25271108 | 0.81 | L3MBTL1 (0.43) | L3MBTL1CTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | L3MBTL1 1303/4885CTSB 302/4885PPARA 2074/4885 |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | L3MBTL1 611/4885CTSB 708/4885PPARA 2904/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | L3MBTL1 944/4885CTSB 1631/4885PPARA 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.